Wird geladen...
Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
Regorafenib is an orally administered inhibitor of protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Phase III studies showed that regorafenib has efficacy in patients with advanced gastrointestinal stromal tumors or treatment‐refractory meta...
Gespeichert in:
| Veröffentlicht in: | Cancer Med |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5119973/ https://ncbi.nlm.nih.gov/pubmed/27734608 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.883 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|